Sanuwave Health, INC 8-K filings

Sanuwave Health announced its second quarter 2026 financial results, reporting a 3% decrease in revenue to $9.7 million, alongside a shift to an operating loss.

Sanuwave Health announced preliminary Q2 2026 revenues are expected to be between $9.6 million and $9.8 million, exceeding its revised guidance.

Sanuwave Health announced updated revenue guidance for Q2 2026, expecting $8.5 - $9.5 million, below previous projections, due to market disruption impacting Ultramist system sales.

Sanuwave Health stockholders elected five directors and ratified the appointment of Baker Tilly US, LLP as the company's independent auditor.

Sanuwave Health announced first-quarter 2026 financial results, showing a 3.1% revenue increase to $9.6 million, with guidance for continued growth.

Sanuwave Health expects Q1 2026 revenue between $9.6 million and $9.7 million, reflecting a 3-4% year-over-year increase.

Sanuwave Health, Inc. announced record revenues for both the fourth quarter and full year 2025, driven by strong UltraMIST system and consumables sales.

SANUWAVE Health, Inc. announced it will restate previously issued financial statements due to an identified historical state sales and use tax liability.

SANUWAVE Health, Inc. announced its decision to hold annual stockholder advisory votes on executive compensation, aligning with stockholder preference.

Sanuwave Health, Inc. announced record third-quarter 2025 revenues of $11.5 million, a 22% increase year-over-year, and provided optimistic Q4 and full-year guidance.

SANUWAVE Health, Inc. announced the termination of its President, Andrew Walko, effective October 24, 2025, with a severance package including cash and continued stock option vesting.

SANUWAVE Health, Inc. announced significant leadership changes, including a new Chief Operating Officer and the termination of its President.

Sanuwave Health, Inc. announced a strategic debt refinancing, replacing its $27.5 million facility with a new $28 million credit facility from J.P. Morgan, reducing overall debt and interest rates.

SANUWAVE Health, Inc. announced the sale of its intravascular shockwave patent portfolio for $5.0 million cash, following a previously granted exclusive license.

SANUWAVE Health, Inc. stockholders approved an increase of 500,000 shares for its 2024 Equity Incentive Plan and re-elected five directors at its annual meeting.

Sanuwave Health, Inc. announced its Q2 2025 financial results, reporting record revenue and significant growth in UltraMist system sales.

SANUWAVE Health, Inc. announced the finalization of a separation and release agreement with former Chief Commercial Officer Nanci Gilmore, including a cash payment of over $112,000 and continued stock option vesting.

SANUWAVE Health, Inc. announced preliminary revenues for the second quarter of 2025 are expected to be between $10.1 million and $10.2 million, marking the highest Q2 revenue in company history and aligning with previous guidance.

SANUWAVE Health, Inc. has announced the scheduling of its 2025 Annual Meeting of Stockholders for August 19, 2025, and established critical deadlines for stockholder participation.

Sanuwave Health, Inc. announced the termination of its Chief Commercial Officer, Nanci Gilmore, and the immediate appointment of Dustin Libby as Executive Vice President of Commercial Operations, signaling a strategic focus on accelerating commercial growth.

SANUWAVE Health, Inc. announced the resignation of director A. Michael Stolarski and the appointment of Gregory Bazar to its Board of Directors, effective May 27, 2025.

SANUWAVE Health, Inc. confirms the engagement of Baker Tilly US, LLP as their independent registered public accounting firm after completion of client acceptance procedures.

SANUWAVE Health, Inc. has dismissed CBIZ CPAs as their independent auditor and engaged Baker Tilly US, LLP, effective with the review of the quarter ending June 30, 2025.

Sanuwave Health reports a 61% increase in Q1 2025 revenue, reaching $9.3 million, marking the highest Q1 revenue in company history.

SANUWAVE Health, Inc. has changed its independent registered public accounting firm from Marcum LLP to CBIZ CPAs, effective April 11, 2025.

SANUWAVE Health reports preliminary Q1 2025 revenues between $9.1 million and $9.3 million, marking a 57% to 61% increase compared to Q1 2024 and the highest Q1 revenue in company history.

Sanuwave, Inc., a subsidiary of Sanuwave Health, Inc., has entered into a 60-month lease agreement for a new headquarters in Eden Prairie, Minnesota, with monthly rent starting at $21,687.25.

SANUWAVE Health reports record Q4 and full-year 2024 revenues, driven by strong UltraMist system sales and consumables, and issues promising revenue guidance for 2025.

Sanuwave Health, Inc. announces its common stock has been approved for listing on the Nasdaq Global Market, with trading expected to commence on March 7, 2025, under the ticker symbol SNWV.

SANUWAVE Health, Inc. reports the departure of Executive Vice President of Sales, Timothy Hendricks, and the terms of his severance agreement.